A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Status:
Recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.

Phase 2

Alector Inc.